cancer_type: CRC

# Gap period options for different rules (Table 1)
gap_period_options:
  gap_treatment_restart: 180  # Option C (Optimal for CRC from Table 1)
  # Alternative options for gap_treatment_restart if you want to test them:
  # gap_treatment_restart_option_A: 60  # Option A
  # gap_treatment_restart_option_B: 90  # Option B

# Options for new biologic agent addition (Table 3)
new_biologic_agent_options:
  after_initial_period: 90    # Option C (Optimal for non-CET/PAN from Table 3)
  # Alternative options for after_initial_period (non-CET/PAN) if you want to test them:
  # after_initial_period_option_A: 28   # Option A
  # after_initial_period_option_B: 90   # Option B (same as C in value, but listed as option B in Table)

  bio_dis1_period: 90        # Option B (Optimal for cetuximab/panitumumab from Table 3)
  # Alternative options for bio_dis1_period (cetuximab/panitumumab) if you want to test them:
  # bio_dis1_period_option_A: 60    # Option A
  # bio_dis1_period_option_C: 180   # Option C

  # Removed redundant 'new_biologic_agent_period' - 'after_initial_period' covers non-CET/PAN biologics


# Options for new chemotherapy agent addition to FLU regimen (Table 3)
new_chemo_agent_options:
  flu_dis_period: 60         # Option A (Optimal for new chemo to FLU regimen from Table 3)
  # Alternative options for flu_dis_period if you want to test them:
  # flu_dis_period_option_B: 90    # Option B
  # flu_dis_period_option_C: 180   # Option C

# Comprehensive drug interchangeability rules for CRC
drug_interchangeability_rules:
  CRC:
    # Fluoropyrimidines (FLU)
    fluoropyrimidines:
      - '5-fluorouracil'
      - 'capecitabine'
      - 'trifluridine'
      - 'tipiracil'
      - 'S-1'  # in some regions
    
    # Anti-EGFR agents
    anti_egfr:
      - 'cetuximab'
      - 'panitumumab'
    
    # Anti-VEGF agents
    anti_vegf:
      - 'bevacizumab'
      - 'aflibercept'
      - 'ramucirumab'
    
    # Other targeted therapies
    other_targeted:
      - 'regorafenib'
      - 'encorafenib'  # for BRAF V600E mutations
    
    # Standard chemotherapy agents
    chemotherapy:
      platinum:
        - 'oxaliplatin'
        - 'cisplatin'
      topoisomerase:
        - 'irinotecan'
      other:
        - 'leucovorin'  # Not a cytotoxic agent but commonly used
    
    # Common combination regimens
    standard_regimens:
      folfox:
        - '5-fluorouracil'
        - 'leucovorin'
        - 'oxaliplatin'
      folfiri:
        - '5-fluorouracil'
        - 'leucovorin'
        - 'irinotecan'
      capox:
        - 'capecitabine'
        - 'oxaliplatin'
      
    # Interchangeable combinations
    combinations:
      - ['oxaliplatin', 'capecitabine']  # CAPOX
      - ['oxaliplatin', '5-fluorouracil'] # FOLFOX
      - ['irinotecan', '5-fluorouracil']  # FOLFIRI
    
    # Treatment sequence rules
    sequence_rules:
      first_line_preferred:
        - 'FOLFOX'
        - 'FOLFIRI'
        - 'CAPOX'
      second_line_common:
        - 'FOLFIRI after FOLFOX'
        - 'FOLFOX after FOLFIRI'
      maintenance_options:
        - 'fluoropyrimidine + bevacizumab'
        - 'fluoropyrimidine monotherapy'

    # Special considerations
    molecular_markers:
      RAS_wildtype:
        preferred_biologics: ['cetuximab', 'panitumumab']
      BRAF_V600E:
        preferred_combination: ['encorafenib', 'cetuximab']